Text version
Hi! Jim Phelps here for the Psychopharmacology Institute. We’ll do a series this month on schizophrenia and other difficult to treat diagnoses. We’ll look at clozapine. Is it a first-line medication? How big an issue is neutropenia? Then we’ll look at some data on depression in schizophrenia and how to handle that. And then we will address another difficult topic—treatment of dementia with acetylcholinesterase inhibitors.
For our first article in this issue of Quick Takes, let’s look at clozapine in the treatment of schizophrenia and related disorders and examine the question of: Where in the lineup does clozapine come? Should it actually be considered as a first-line agent? Somewhat to my surprise, there are actually enough studies to do a meta-analysis on this question.
The first article is a meta-analysis from the Netherlands. It was led by Cynthia Okhuijsen-Pfeifer, and she and her colleagues examined outcomes when clozapine was used
Unlock this Quick Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
